Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL
March 01, 2021 08:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL
March 01, 2021 08:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
Ritter Pharmaceuticals, Inc. Announces Expected Closing of Merger Transaction with Qualigen, Inc.
May 22, 2020 12:35 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 22, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), today announced that its pending merger transaction...
Ritter Pharmaceuticals, Inc. Announces Stockholder Approval of Proposals Required for Merger Transaction with Qualigen, Inc.
May 19, 2020 08:00 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 19, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), announced today that, based upon the final vote count...
Ritter Pharmaceuticals, Inc. Announces Adjournment of its Special Meeting
May 14, 2020 14:13 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 14, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter” or the “Company”), today announced that it has adjourned its special meeting of stockholders,...
Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Stockholders’ Equity Requirement for Continued Listing
May 11, 2020 08:00 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 11, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), today announced that it has received written notice from the...
Leading Independent Proxy Advisory Firms Recommend Ritter Pharmaceuticals Shareholders Vote in Favor of its Merger and Each of the Merger Proposals
May 06, 2020 09:15 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 06, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), today announced that Institutional Shareholder Services Inc....
Ritter Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2020
May 01, 2020 17:34 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 01, 2020 (GLOBE NEWSWIRE) -- Form S-4 Declared Effective by the SEC and Ritter/Qualigen Merger Voting is Underway Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter...
Ritter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger with Biotech Company, Qualigen Inc.
April 28, 2020 07:30 ET
|
Ritter Pharmaceuticals, Inc.
The merger CANNOT be consummated without the approval of EACH of the proposals being voted on at the Special Meeting, including approval of a reverse stock split. LOS ANGELES, April 28, 2020 ...
Ritter Pharmaceuticals, Inc. Announces Form S-4 Registration Statement Declared Effective by SEC
April 16, 2020 14:07 ET
|
Ritter Pharmaceuticals, Inc.
Special Meeting of Ritter Pharmaceuticals, Inc. Stockholders to Vote on Proposed Merger Scheduled for May 14, 2020 LOS ANGELES , April 16, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc....